Eli Lilly And Company revenue by segment LLY

Annual Quarterly

Eli Lilly And Company splits its revenue into 13 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Cardiometabolic Health at $19.8 billion, 81% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	86,462	24,397	22,974	19,799	19,292	17,601	15,558	12,729	13,533
Cardiometabolic Health	—	19,764 +50.0% share 81.0%	18,353 share 79.9%	15,760 +71.2% share 79.6%	—	13,178 share 74.9%	—	9,208 share 72.3%	—
Product	—	—	—	—	18,300 +52.2% share 94.9%	—	—	—	12,025 share 88.9%
Mounjaro	—	—	—	—	—	—	5,199 share 33.4%	—	—
Other Cardiometabolic Health	—	1,207 +13.4% share 4.9%	1,031 +5.2% share 4.5%	905 -4.2% share 4.6%	—	1,064 share 6.0%	980 share 6.3%	945 share 7.4%	—
Other Oncology	—	1,089 +16.2% share 4.5%	1,096 +18.6% share 4.8%	966 +22.4% share 4.9%	—	937 share 5.3%	924 share 5.9%	789 share 6.2%	—
Trulicity	—	904 -14.1% share 3.7%	1,219 +11.6% share 5.3%	—	—	1,052 share 6.0%	1,092 share 7.0%	1,095 share 8.6%	—
Taltz	—	856 -5.1% share 3.5%	856 +0.9% share 3.7%	733 -3.8% share 3.7%	—	902 share 5.1%	848 share 5.5%	762 share 6.0%	—
Other Immunology	—	579 +25.6% share 2.4%	561 +37.5% share 2.4%	470 +44.2% share 2.4%	—	461 share 2.6%	408 share 2.6%	326 share 2.6%	—
Neuroscience	—	444 +40.5% share 1.8%	429 +24.7% share 1.9%	382 +40.4% share 1.9%	—	316 share 1.8%	344 share 2.2%	272 share 2.1%	—
Other Product Total	—	—	—	—	—	337 share 1.9%	—	—	—
Olumiant	—	—	—	—	—	—	—	—	262 share 1.9%
Basaglar	—	—	—	—	—	—	—	—	177 share 1.3%
Product And Service Other	—	154 -54.3% share 0.6%	205 +1.5% share 0.9%	187 -12.2% share 0.9%	—	337 share 1.9%	202 share 1.3%	213 share 1.7%	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: LLY (NYSE)
Fiscal year ends: December 31
Incorporated in: IN
Headquarters: Indianapolis, IN
SEC filer status: Large accelerated filer
SEC CIK: 59478
Former names: LILLY ELI & CO (until Oct 25, 2019); LILLY ELI & CO ET AL (until Oct 14, 1994)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.